AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05147233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone
Study NCT05147233 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Placebo
Description: Placebo comparator
Study NCT06194591 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NephrospecTM, low-intensity extracorporal shockwave therapy device
Description: Patients will receive 6 Li-ESWT treatments with the NephrospecTM device over three consecutive weeks, with a minimal recess of 24 hours between treatments and a maximum of 3 sessions per week.~Three hundred shockwaves will be applied by the PI or co-PI to each one of 8 pre-selected regions of each kidney, under ultrasound control, with the patient in the prone position. No local anaesthesia is needed. Total treatment time of one session is 30 minutes. The participant will remain under supervision for another 30 minutes and will be discharged hereafter.
Study NCT06194591 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham-Device
Description: The sham device is the NephrospecTM applicator with an internal barrier to prevent shockwaves to pass through to the patient.
Study NCT06322875 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Recombinant type III humanized collagen solution for injection
Description: Each subject will receive one injection of Recombinant type III humanized collagen solution for injection on the whole face
Study NCT06322875 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Recombinant type III humanized collagen solution for injection
Description: Each subject will receive one injection of Recombinant type III humanized collagen solution for injection on the whole face
Study NCT06322875 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SkinCeuticals recombinant humanized collagen (RHC) serum
Description: Subjects received SkinCeuticals recombinant humanized collagen (RHC) serum application on the test side face
Study NCT06322875 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Regular face cream smear
Description: Subjects received Regular face cream smear application on the whole face
Study NCT06322875 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Regular face cream smear
Description: Subjects received Regular face cream smear application on the whole face
Study NCT06439368 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dezocine
Description: At the end of the operation, dezocine 1.0 mg/kg + sufentanil 2.0 ug/kg (prepared as 200 ml, background volume 2 ml/h, single dose 2 ml/time, locking time 15 min) was uniformly administered by PCIA; 3 ml test dose was administered immediately after the analgesic pump was connected at the end of the operation, and continuous analgesia was performed for 48 hours after the operation.
Study NCT06439368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dezocine
Description: At the end of the operation, dezocine 1.0 mg/kg + sufentanil 2.0 ug/kg (prepared as 200 ml, background volume 2 ml/h, single dose 2 ml/time, locking time 15 min) was uniformly administered by PCIA; 3 ml test dose was administered immediately after the analgesic pump was connected at the end of the operation, and continuous analgesia was performed for 48 hours after the operation.
Study NCT05776849 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flipped classroom
Description: Educational presentation, visuals and videos (her own video explaining episiotomy application and repair and other videos shared with the traditional group) prepared for the students on episiotomy were shared one week before the episiotomy application.
Study NCT05749614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine cream
Description: Group 1 was given 1 ml of 5% lidocaine cream on demand. They were instructed to apply the lidocaine cream evenly in a circular pattern to the glans penis without precise application to the sensitive area of the glans penis. The treatment lasted for a total of 4 weeks.
Study NCT05749614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine cream
Description: Group 2 had a penile biological vibration threshold test performed to detect loci with a lower threshold. They were instructed to apply 1 ml of 5% lidocaine cream to the sensitive loci on the glans penis for 4 weeks.
Study NCT06038331 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SclerFIX-IP
Description: Decellularized, viro-inactivated, freeze-dried and sterile allogeneic graft of amniotic membrane of umbilical cord used as an interposition implant in the STT joint
Study NCT05103345 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: SGN1
Description: SGN1,will be administered intratumorally,which dosage is 0.9-2.0×109 cfu /vial.
Study NCT05707780 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resin-matrix
Description: posterior crowns
Study NCT05707780 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Monolithic zirconia
Description: posterior crowns
Study NCT06772506 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non Surgical Periodontal Treatment includes post operative mouth wash with Listerine® (ethanol 21.6%, methyl salicylate 0.06%, menthol 0.042%, thymol 0.064% and eucalyptol 0.092%)
Description: non-surgical technique plus splint and ultrasonic device with 200 mg Tetracycline
Study NCT06772506 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Minimally invasive non-surgical technique with mini five and after five minimally invasive instrument plus splint
Description: minimally invasive instruments, with mini five and after five minimally invasive instrument ultrasonic scaler device, conventional radiographic device and periodontal instruments with post-operative 1 gram penicillin for 3 days regulatory Statement: This study does not include an FDA-regulated device intervention, as the tools utilized are not the subject of investigation but are instead employed as part of routine clinical
Study NCT06772142 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Peripheral Nerve Stimulation
Description: Peripheral Nerve Stimulation
Study NCT05707780 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Metal-ceramic
Description: posterior crowns
Study NCT05789017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone and Mycophenolate Mofetil
Description: Patients are treated with glucocorticoids and mycophenolate mofetil in remission induction period (6 months), during which glucocorticoids are tapered regularly and discontinued in 6 months.
Study NCT05789017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Patients are treated with low dose mycophenolate (1-1.5g/day) during remission maintenance period for 12 months.
Study NCT05789017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leflunomide
Description: Patients are treated with leflunomide (20 mg/day) during remission maintenance period for 12 months.
Study NCT04751162 — intervention group
Intervention type: DEVICE
Intervention: Actigraphy device (wearable) and mobile application
Description: Participants will be asked to wear an actigraphy device (wearable) and to install a mobile application on their smartphones (cf. Broderick et al., 2019) for tracking PA, SQ and symptoms for 3 weeks
Study NCT05634759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin for Routine Community-wide MDA
Description: Oral azithromycin, also known as the brand name Zithromax®, is a macrolide antibiotic and is used in the treatment of active trachoma. The recommended dosage for the treatment of trachoma is a single dose of 20mg/kg of body weight and is implemented by a Age-height based dosing strategy for the trachoma MDA campaigns. Oral azithromycin can be administrated in either tablet form or powder for oral suspension (POS). Zithromax® is donated by Pfizer Inc through the International Trachoma Initiative (ITI) to the South Sudan Federal Ministry of Health to use in community-wide MDA throughout South Sudan.
Study NCT05634759 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin for Routine Community-wide MDA
Description: Oral azithromycin, also known as the brand name Zithromax®, is a macrolide antibiotic and is used in the treatment of active trachoma. The recommended dosage for the treatment of trachoma is a single dose of 20mg/kg of body weight and is implemented by a Age-height based dosing strategy for the trachoma MDA campaigns. Oral azithromycin can be administrated in either tablet form or powder for oral suspension (POS). Zithromax® is donated by Pfizer Inc through the International Trachoma Initiative (ITI) to the South Sudan Federal Ministry of Health to use in community-wide MDA throughout South Sudan.
Study NCT05634759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Two Additional Rounds of Azithromycin for Children
Description: An additional round of treatment will be given one week after the routine community-wide MDA, and a second additional round will be given two weeks later (3 weeks after the routine community-wide MDA).
Study NCT05634759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin for Second Community-wide MDA
Description: A second community-wide MDA will be given 6 to 8 months after the routine community-wide MDA. The timing of the second MDA will depend on local conditions and logistical concerns.
Study NCT06770049 — intervention group
Intervention type: BEHAVIORAL
Intervention: Standard Lifestyle Intervention (SLI) program
Description: Subjects will receive recommendations for calorie and macronutrient intake, physical activity, and behavioral skills to be followed for 12 months and will be delivered by a multidisciplinary team of obesity experts in a 12-month structured follow up. Participants will meet with a registered dietician as well as member of the study team to learn more about their intervention. Diets will be prescribed for each participant with a 30% calorie deficit calculated from measured REE. Macronutrient composition will be guided based on the patient preference. Participants will be prescribed 150 minutes of physical activity per week (spread across 4-5 days) and recommendations to reach 10,000 steps daily. During the first 12 weeks, participants will be scheduled a 12-week behavioral program focusing on self-monitoring and stimulus control using cognitive-behavioral approaches to promote adherence to diet and exercise prescriptions.
Study NCT06770049 — intervention group
Intervention type: BEHAVIORAL
Intervention: Phenotype-tailored Lifestyle Intervention (PLI) program
Description: Subjects will receive recommendations for calorie and macronutrient intake, physical activity, and behavioral skills to be followed for 12 months and will be delivered by a multidisciplinary team of obesity experts. The recommendations will be determined a priori to tailor for each obesity phenotype
Study NCT06770803 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: High Pressure Pneumoperitoneum
Description: The objective of this trial is to determine whether the maintenance of a low intraperitoneal insufflation pressure (IIP) of ≤10 mmHg during the parenchymal transection phase of conventional and robotic-assisted laparoscopic liver resection is non-inferior to a higher IIP of ≥14 mmHg in terms of intraoperative blood loss, gas embolisms, perioperative morbidity, and mortality.
Study NCT05841095 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ISA104
Description: SLP vaccine
Study NCT05841095 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline solution (0.9% NaCl)
Study NCT05824754 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Just-In-Time-Adaptive-Intervention (JITAI)
Description: Behavioral: MiWaves behavioral messages~Participants will be using the MiWaves mobile app for 30 days. When a participant is assigned to receive a message, a message will be randomly selected from a pool of intervention message sets. Messages are based in motivational interviewing and include affect management and behavioral economic strategies.
Study NCT06032442 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ARTNEO
Description: Dietary Supplement: undenaturated collagen type II, methylsulfonylmethane, boswellia serrata, vitamin D3 (cholecalciferol), vitamin C (ARTNEO)~Release form: capsules with an average weight of 585 mg. Active ingredients: MCM (methylsulfonylmethane) 300 mg, vitamin C (ascorbic acid) 80 mg, boswellia extract (65% boswellic acids) 50.05 mg, undenatured (native) type II collagen 40 mg, vitamin D3 (cholecalciferol) 400 IU.~Suggested Use: Adults, 1 capsule daily with meals.
Study NCT06032442 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artra
Description: Active ingredients:~Glucosamine hydrochloride 500 mg Chondroitin sulfate sodium 500 mg~Excipients:~dibasic calcium phosphate, microcrystalline cellulose, croscarmellose sodium, stearic acid, magnesium stearate.~Orally; adults and children over 15 years of age are prescribed 1 tablet 2 times a day for the first three weeks; 1 tablet 1 time per day for the next weeks and months.
Study NCT04887831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trilaciclib
Description: Trilaciclib administered IV prior to chemotherapy and avelumab maintenance therapy on each day chemotherapy and avelumab maintenance therapy is administered.
Study NCT04887831 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine administered IV on Day 1 and Day 8 of each 21-day cycle
Study NCT04887831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine administered IV on Day 1 and Day 8 of each 21-day cycle
Study NCT04887831 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin administered IV on Day 1 of each 21-day cycle
Study NCT04887831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin administered IV on Day 1 of each 21-day cycle
Study NCT04887831 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin administered IV on Day 1 of each 21-day cycle
Study NCT04887831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin administered IV on Day 1 of each 21-day cycle
Study NCT04887831 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avelumab
Description: Avelumab will be dosed on Day 1 of each 14-day maintenance cycle
Study NCT04887831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab will be dosed on Day 1 of each 14-day maintenance cycle
Study NCT05999318 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: active continuous Theta Burst Stimulation
Description: Each patient will receive two 600-pulse cTBS stimulations per day, parted by a 15-minute rest period (a total of 1200 pulses daily), for 3-week treatment, with 5 consecutive workdays each week.
Study NCT05999318 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham continuous Theta Burst Stimulation
Description: Each patient will receive two sham 600-pulse cTBS stimulations per day, parted by a 15-minute rest period (a total of 1200 pulses daily), for 3-week treatment, with 5 consecutive workdays each week.
Study NCT04696640 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Remote Patient Monitoring
Description: Participants' glucose data will be monitored by the study team using population analytic reports. Participants who either have excessive hypoglycemia or hyperglycemia on these reports will be contacted by a pediatric endocrinologist (the principal investigator) to discuss any necessary adjustments to their home diabetes management plans. This intervention will be in addition to their usual care (regular visits at the UC Davis Pediatric Endocrinology clinic).
Study NCT05048719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3502970
Description: Administered orally
Study NCT05048719 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dulaglutide
Description: Administered subcutaneously
Study NCT05048719 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study NCT05048719 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered subcutaneously
Study NCT05715112 — intervention group
Intervention type: PROCEDURE
Intervention: Graded Motor Imagery
Description: GMI consisting of education, sensory integration of the foot using contact, flooring samples, immersion, and two point discrimination.
Study NCT05776095 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cataract surgery
Description: Subjects will undergo surgery to remove cataract (the cloudy lenses) via phacoemulsification, and implant the Eyedeal® Model PX65AS1 IOL in the eye capsule.
Study NCT05776095 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eyedeal® Model PX65AS1 IOL
Description: Subjects will undergo surgery to remove cataract (the cloudy lenses) via phacoemulsification, and implant the Eyedeal® Model PX65AS1 IOL in the eye capsule.
Study NCT04708977 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: One-level lateral lumbar interbody fusion with Indirect Decompression
Description: One-level lateral lumbar interbody fusion, with or without percutaneous posterior instrumentation. Thorough discectomy will be performed using lateral access. Fusion will then be performed using lateral access interbody cage and allograft bone graft with or without use of recombinant human bone morphogenic protein 2.
Study NCT04708977 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: One-level lateral lumbar interbody fusion with Direct Decompression
Description: One-level lateral lumbar interbody fusion, with or without percutaneous posterior instrumentation. Thorough discectomy will be performed using lateral access instruments. Fusion will then be performed using lateral access interbody cage and allograft bone graft with or without use of recombinant human bone morphogenic protein 2.~Additionally, direct decompression through midline or parasagittal approach will be utilized. A unilateral laminotomy or complete bilateral laminectomy may be performed.
Study NCT05546580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iadademstat
Description: iadademstat oral solution
Study NCT05546580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilteritinib Oral Tablet
Description: 120 mg Gilteritinib
Study NCT05020015 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TAK-007
Description: TAK-007 intravenous injection.
Study NCT05020015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy Agents
Description: Fludarabine and cyclophosphamide as per standard of care.
Study NCT06027645 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Crawling stimulation with a mini-skateboard (i.e. the crawliskate)
Description: Consists of 8 weeks of daily training. Infants benefit from a 10 minutes session everyday at home with either a trained therapist or his/her parents. Parents are trained by the therapist at the begining of the 8 weeks. During each session the infant is prone wrapped on a mini-skateboard (i.e. the crawliskate) and has to produce flexion and extension movements with his four limbs in order to move forward with the assistance of the adult (therapist or parent).
Study NCT06286748 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Beetroot juice
Description: Beetroot juice + exercise. Patients will ingest 200ml of beet juice (Beta vulgaris) containing approximately 300mg of nitrate (NO3-), and after 2 hours they will be instructed to perform an exercise protocol.
Study NCT06286748 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo + exercise. Patients will ingest 200ml of placebo (water, without nitrate (NO3-)), and after 2 hours they will be instructed to perform an exercise protocol.
Study NCT05329935 — intervention group
Intervention type: BIOLOGICAL
Intervention: Cultured Thymus Tissue
Description: Product will be surgically administered into the quadriceps
Study NCT05321836 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glucosamine Chondroitin
Description: control group
Study NCT05321836 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: glucosamine chondritin & Physiotherapy
Description: experimental group
Study NCT04957134 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture
Description: The acupoints of electro-acupuncture will be selected as Zusanli ,Sanyinjiao ,Zhongwan , Tianshu , Shuifen , Daheng ,Daimai , Shuidao ,Huaroumen and Fujie . We will deliver electrical stimulation with dense-disperse waves at 50 Hz and 10 V through the electrical acupuncture stimulation instrument to the abdominal points. The bodily needles will be retained for 30 minutes . Electro-acupuncture treatment will be applied 3 times a week, once every other day, for 8 consecutive weeks.
Study NCT04957134 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham electro-acupuncture
Description: The acupoints of sham electro-acupuncture will be selected as nonacupoints . The internal output power cord of the electrical acupuncture stimulation instrument will be interrupted. The bodily needles will be retained for 30 minutes . Sham acupuncture treatment will be applied 3 times a week, once every other day, for 8 consecutive weeks.
Study NCT06286189 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo capsule taken 30 min before sleep
Study NCT05261269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAN-222
Description: Administered IV every week to subjects
Study NCT05261269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Administered orally once daily
Study NCT06286189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trazodone Hydrochloride
Description: Trazodone 100 mg 30 min before sleep